delavirdine (rescriptor) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. .   NCATS

Chemistry

  • SMILES: CC(C)Nc1cccnc1N2CCN(CC2)C(=O)c3cc4cc(NS(=O)(=O)C)ccc4[nH]3
  • InChIKey: WHBIGIKBNXZKFE-UHFFFAOYSA-N
  • Mol. Mass: 456.57
  • ALogP: 2.72
  • ChEMBL Molecules:
    delavirdine  
    delavirdine mesylate  
More Chemistry

Pharmacology

Alternative names

1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1h-indol-2-yl)carbonyl)piperazine | 2-(4-(5-methanesulfonamido-1h-indol-2-ylcarbonyl)-1-piperazinyl)-n-(1-methylethyl)-3-pyridinamine | delavirdin | delavirdina | delavirdine | delavirdine mesilate | delavirdine mesylate | delavirdinum | n-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1h-indol-5-yl)methanesulfonamide | (n-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1h-indol-5-yl] methanesulfonamide) | n-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1h-indol-5-yl}-methanesulfonamide | rescriptor | u-90152 | u-90152s | u-90152t

Organizations (9)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

HIV Infections (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

HIV Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue